• PharmaInformatic entwickelt Expertensysteme für forschende pharmazeutische Unternehmen. Unsere Expertensysteme erkennen frühzeitig die sinnvollen Substanz-Kandidaten und senken somit die Entwicklungskosten neuer Medikamenten drastisch.

    Die Plattform-Technologie des Unternehmens beinhaltet Millionen von Substanzen verknüpft mit experimentellen Daten sowie mehrere Tausend 3D-Modelle von Biomolekülen. Proprietäre Methoden der ChemieInformatik und BioInformatik ermöglichen die Prognose des Wirkungsspektrum einer Substanz sowie dessen pharmakologische Eigenschaften. (mehr...)

  

 
MolScore-Drugs
An expert system to identify and prioritise suitable drug candidates.

  

 
MolScore-Antibiotics
 An expert system for
antibiotic research.

 


MolScore-Antivirals
An expert system for
antiviral research.

© Copyright 2004-2010 PharmaInformatic Boomgaarden. All rights reserved.         Site map           Contact         Terms of Use         Imprint        


Meet representatives of PharmaInformatic

 To arrange a meeting, please contact us.
 

 
Direct access to all pages:



Site map
 

    PharmaInformatic develops expert systems for pharmaceutical companies. Our expert systems identify promising drug candidates at the earliest stage. This reduces failure rates and saves time and money.

    Our platform technology contains millions of substances together with experimental data and thousands of 3D-models of biomolecules. Proprietary methods based on chemInformatics and bioInformatics allow the prediction of biological activity of a substance and its pharmacological properties.

News:


Successful detection of novel clinical candidates by MolScore Antivirals (evaluation results).

Successful detection of novel clinical candidates by MolScore Antibiotics (evaluation results).

    PharmaInformatic provides cheminformatic services and predictive tools to improve drug discovery.

    In 2004 we started to develop a comprehensive and highly annotated ADME/Tox database. This unique data collection is now, to our knowledge, the largest pharmacokinetic data source worldwide.

    Based on this unique pharmacokinetic data collection reliable tools  have been developed to predict ADME/Tox-properties and to identify and prioritise promising drug candidates.